© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 4, 266-276,
February 21, 2001
© 2001 Oxford University Press
REVIEW |
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Affiliations of authors: M. Höckel, Department of Obstetrics and Gynecology, University of Leipzig, Germany; P. Vaupel, Institute of Physiology and Pathophysiology, University of Mainz, Germany.
Correspondence to: Professor Dr. Peter Vaupel, Institute of Physiology and Pathophysiology, University of Mainz, Duesbergweg 6, 55099 Mainz, Germany (e-mail: VAUPEL{at}mail.uni-mainz.de).
 |
ABSTRACT |
|---|
 TopNotes Abstract IntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
Tissue hypoxia results from an inadequate supply of oxygen (O2) that compromises biologic functions. Evidence from experimental and clinical studies increasingly points to a fundamental role for hypoxia in solid tumors. Hypoxia in tumors is primarily a pathophysiologic consequence of structurally and functionally disturbed microcirculation and the deterioration of diffusion conditions. Tumor hypoxia appears to be strongly associated with tumor propagation, malignant progression, and resistance to therapy, and it has thus become a central issue in tumor physiology and cancer treatment. Biochemists and clinicians (as well as physiologists) define hypoxia differently; biochemists define it as O2-limited electron transport, and physiologists and clinicians define it as a state of reduced O2 availability or decreased O2 partial pressure that restricts or even abolishes functions of organs, tissues, or cells. Because malignant tumors no longer execute functions necessary for homeostasis (such as the production of adequate amounts of adenosine triphosphate), the physiology-based definitions of the term "hypoxia" are not necessarily valid for malignant tumors. Instead, alternative definitions based on clinical, biologic, and molecular effects that are observed at O2 partial pressures below a critical level have to be applied.
|
INTRODUCTION |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
Traditionally, tumor hypoxia has been considered a potential therapeutic problem because it renders solid tumors more resistant to sparsely ionizing radiation (1–3). More recent experimental and clinical studies [reviewed in (4–10)] suggest that intratumoral oxygen levels may influence a series of biologic parameters that also affect the malignant potential of a neoplasm.
Sustained hypoxia in a growing tumor may cause cellular changes that can result in a more clinically aggressive phenotype (11–15). During the process of hypoxia-driven malignant progression, tumors may develop an increased potential for local invasive growth (16,17), perifocal tumor cell spreading (11,18), and regional and distant tumor cell spreading (12,13,19–21). Likewise, intrinsic resistance to radiation and other cancer treatments may be enhanced (18,22–29).
Hypoxia-induced or hypoxia-mediated changes of 1) the proteome (i.e., the complete set of proteins within a cell at a given time) of the neoplastic and stroma cells and 2) the genome of the genetically unstable neoplastic cells may explain the fact that tumor oxygenation is associated with disease progression, a link that has been demonstrated for a variety of human malignant tumor types (11–15). The first goal of this review is to compile current results from experimental and clinical studies, illustrating the interaction between hypoxia and the phenomena of malignant progression and resistance toward oncologic treatment.
In an increasing number of reports on tumor oxygenation, the term "hypoxia" has been used in a somewhat careless manner without due consideration of the clear definitions for certain experimental conditions and scientific questions. Different researchers discussing the problem of tumor hypoxia may use the term "hypoxia" in different ways, thus leading to a "Babylonian confusion." The second goal of this review is, therefore, to shed some light on the pitfalls of the casual use of the term "tumor hypoxia." Because evidence of the fundamental biologic and clinical importance of tumor hypoxia is increasing, molecular biologists, physiologists, and clinicians should take care to communicate on the same "wavelength" and clearly define what they mean when they use the term "tumor hypoxia."
|
DEFINITION AND CAUSATIVE MECHANISMS |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
Tissue hypoxia results from the inadequate supply of oxygen (O2) that compromises biologic functions (30). Hypoxia can be caused by a number of factors, such as 1) low O2 partial pressure (O2 tension) in arterial blood due to, e.g., pulmonary diseases or high altitude (hypoxemic hypoxia); 2) reduced ability of blood to carry O2 as a result of anemia, methemoglobin formation, or carbon monoxide poisoning (anemic hypoxia); 3) reduced tissue perfusion, generalized or local (circulatory or ischemic hypoxia); 4) deterioration of the diffusion geometry, e.g., increased diffusion distances, concurrent versus countercurrent blood flow within microvessels (diffusional hypoxia); or 5) inability of cells to use O2 because of intoxication, as in cyanide poisoning (histotoxic or cytotoxic hypoxia). Because of finely tuned regulatory processes, increases in tissue O2 consumption are generally matched by an increase in blood flow and, therefore, do not usually lead to hypoxia unless the system regulating blood flow fails to meet the increased O2 demand of the tissue in question.
Biochemists usually define hypoxia as O2-limited electron transport (31). Physiologists and clinicians define hypoxia as a state of reduced O2 availability or decreased O2 partial pressures below critical thresholds, thus restricting or even abolishing the function of organs, tissues, or cells (32–34). Anoxia describes the state where no O2 is detected in the tissue (O2 partial pressure = 0 mm of mercury [mmHg]).
In solid tumors, oxygen delivery to the respiring neoplastic and stromal cells is frequently reduced or even abolished by a deteriorating diffusion geometry, severe structural abnormalities of tumor microvessels, and disturbed microcirculation (35). In addition, anemia and the formation of methemoglobin or carboxyhemoglobin reduce the blood's capacity to transport O2. As a result, areas with very low (down to zero) oxygen partial pressures exist in solid tumors, occurring either acutely or chronically. These microregions of very low or zero O2 partial pressures are heterogeneously distributed within the tumor mass and may be located adjacent to regions with normal O2 partial pressures. In contrast to normal tissue, neoplastic tissue can no longer fulfill physiologic functions. Thus, tumor hypoxia cannot be defined by functional deficits, although areas of necrosis, which are often found in tumor tissue on microscopic examination, indicate the loss of vital cellular functions.
|
METABOLIC HYPOXIA IN SOLID TUMORS |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
When an unrestricted supply of oxygen is available, for most tumors, the rate of O2 consumption (respiration rate) and adenosine triphosphate (ATP) production is comparable to that found in the corresponding normal tissue, despite the deregulated organization of cells in malignant tumors. To maintain a sufficient energy supply for membrane transport systems and synthesis of chemical compounds, an adequate supply of O2 is required.
In hypoxia, the mitochondrial O2 consumption rate and ATP production are reduced, which hinders inter alia active transport in tumor cells. Specifically, major effects of the reduced production of ATP are 1) collapse of Na+ and K+ gradients, 2) depolarization of membranes, 3) cellular uptake of Cl-, 4) cell swelling, 5) increased cytosolic Ca2+ concentration, and finally, 6) decreased cytosolic pH, resulting in intracellular acidosis in tumor cells.
According to the definition given above, hypoxia is present in tumors when the O2 partial pressure falls below a critical value causing the O2 consumption rate or ATP production rate of a cell or a tissue to decrease progressively. On the basis of experimental results from isolated xenografted human breast cancer tissue (36,37), tumor tissue hypoxia with reduced O2 consumption rates is expected when the O2 partial pressure in the blood at the venous end of the capillaries (end-capillary blood) falls below 45–50 mmHg (Table 1
). This critical threshold, however, has been validated only under the following boundary conditions: a tumor blood flow rate of 1 mL/g per minute, a hemoglobin concentration of 140 g/L, and an arterial O2 partial pressure of 90–100 mmHg. Reducing the perfusion rate to 0.3 mL/g per minute yields an hypoxic tissue fraction of approximately 20% (48). When the hemoglobin concentration falls below 100 g/L or the normal O2 content of arterial blood decreases (hypoxemia), the relative proportion of hypoxic tissue substantially increases in the experimental tumor system described.
|
On a global tissue level, the critical O2 partial pressure in tumors, below which the detrimental changes associated with reduced O2 consumption have been observed, is 8–10 mmHg (Table 1
). Measurements of the microregional distributions of ATP by quantitative bioluminescence and photon imaging in rodent tumors have shown that the concentration of ATP is relatively constant (1.0–1.8 mM) as long as an adequate supply of oxygen (i.e., comparable to that of normal tissues or organs) can be maintained (49,50). In FSaII murine fibrosarcomas growing subcutaneously in mice, relatively constant ATP levels were present as long as the median O2 partial pressure was 10 mmHg or higher [Fig. 1 and (38)]. Similar results were obtained in rat tumors when the global ATP content was evaluated with high-performance liquid chromatography (39,40). Median O2 partial pressures of approximately 10 mmHg thus appear to represent a critical threshold for energy metabolism in FSaII tumors. At higher median O2 tensions, the levels of ATP, phosphomonoesters, and total inorganic phosphate were relatively constant, coinciding with intracellular alkalosis or neutrality and a stable ATP/inorganic phosphate ratio, energy charge, and phosphorylation potential. Median O2 partial pressures of less than 10 mmHg result in intracellular acidosis, ATP depletion, a drop in the energy supply, and increasing levels of inorganic phosphate (Fig. 1).
|
Oxidative phosphorylation for ATP formation will continue to a cellular O2 partial pressure of 0.5–10 mmHg [Table 1
and (42–45)]. Certainly, the threshold O2 partial pressure below which oxidative phosphorylation ceases is dependent on the cell line investigated and its respiratory capacity, the type of medium and substrate chosen, the temperature and pH of the suspending medium, and even the type and accuracy of the setup used to measure O2 consumption rates.
Mitochondrial oxidative phosphorylation is limited at O2 partial pressures of less than approximately 0.5 mmHg [Table 1 and (32,45)]. Above this threshold, mitochondria should function physiologically. Again, this critical threshold depends on the actual substrate supply, on the pH of the suspending medium, and on the technique used to measure O2. Cytochromes aa3 and c in ascites cells require O2 partial pressures of greater than 0.02–0.07 mmHg [Table 1 and (32,46,47)] to maintain respiration. At O2 partial pressures above this range, cytochromes are fully oxidized. Spectrophotometric measurements on living and rapidly deep-frozen tissues indicate that the same is true in vivo.
From this rather rudimentary summary of critical O2 partial pressures for metabolic hypoxia, there does not appear to be a single hypoxic threshold that is generally applicable. Hypoxic thresholds range from 45–50 mmHg in end-capillary blood to 0.02 mmHg in cytochromes (see Fig. 4). Furthermore, such data on hypoxic thresholds in a given tissue do not take into consideration the existence of severe heterogeneities even on a microscopic level related to variable O2 demands and O2 supply.
|
In this discussion of hypoxic thresholds, it is important to note that, for any functional parameter, a sharp threshold between hypoxia and normoxia does not exist and should not be expected. This review deals with the problem of hypoxia as a whole, encompassing mild, moderate, and severe hypoxia (divisions that are not well defined). Approaches in which oxygen effects have been defined under in vitro conditions by using half-maximum values (e.g., in ionizing radiation) have proven useful in some instances, such as comparing radiosensitivity of different cell lines under identical boundary conditions. However, use of half-maximal values in a more general discussion of hypoxia is not very informative because these values do not give the O2 levels at which hypoxia starts and becomes a biologic problem.
|
METHODS FOR DETECTION OF TUMOR HYPOXIA |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
During the past decade, the oxygenation status of solid tumors has been evaluated by investigators in many specialized centers. Despite various limitations of the techniques used, a number of key findings have been described as follows: 1) Most tumors have lower median O2 partial pressures than their tissue of origin; 2) many solid tumors contain areas of low O2 partial pressure that cannot be predicted by clinical size, stage, grade, histology, and site; 3) tumor-to-tumor variability in oxygenation is usually greater than intratumor variability in oxygenation; and 4) recurring tumors have a poorer oxygenation status than the corresponding primary tumors [reviewed in (4)].
Assessment of the tumor oxygenation status by invasive and noninvasive procedures has been reviewed [(51–54) and Table 2]. Many methods can detect tumor hypoxia. Which method is most appropriate for a particular experimental or clinical need will depend on the feasibility of the approaches available in terms of invasiveness and the degree of resolution required, on whether measurement of a direct or indirect parameter is necessary, and, of course, on financial considerations.
|
The present "gold standard" is intratumor polarographic measurement of O2 partial pressures by using microsensor techniques that adhere to the systematic random sampling principle (53). However, no single method will probably be suitable for all situations; therefore, where possible, use of more than one technique may be advisable. In all instances, careful interpretation of the data obtained is paramount, and researchers should bear in mind the exact parameters measured and the limitations of the specific methods used.
|
HYPOXIA-MEDIATED PROTEOME CHANGES AND TUMOR PROPAGATION |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
The intrinsic ability of a tumor to propagate by means of local destructive growth and dissemination is the hallmark of malignant disease. The hypoxic microenvironment in solid tumors, which affects neoplastic cells and non-neoplastic stromal cells such as macrophages and fibroblasts, should have profound effects on tumor propagation if one considers the proteome changes of cells demonstrated under hypoxic conditions in vitro. The proteome changes may result from the stimulation or inhibition of gene expression and from posttranscriptional and posttranslational effects induced by hypoxia or anoxia (Fig. 2
).
|
Anoxia/hypoxia-induced proteome changes in neoplastic and stromal cells may lead to the arrest or impairment of neoplastic growth through molecular mechanisms, resulting in cellular quiescence, differentiation, apoptosis, and necrosis (97–101). Cells exposed to hypoxia are generally arrested at the G1/S-phase boundary (97). O2 partial pressures of 0.2–1 mmHg disproportionately lengthen the G1 phase or arrest cells in the G1 phase (102–104). Above this hypoxic threshold, variations in O2 partial pressure should have only negligible effects on the proliferation rate. Under anoxia, most cells are arrested immediately, regardless of their position in the cell cycle.
Binding of the hypoxic marker pimonidazole to suprabasal cells in epithelia supports the hypothesis that hypoxia may act as a morphogen to induce the terminal differentiation of cells (85,100). This observation appears to have a counterpart in well-differentiated squamous cell cancer, where squamous cell differentiation is consistently observed in tumor areas several cell layers away from the nearest blood vessels (Höckel M: unpublished observations). The molecular mechanisms of hypoxia-induced terminal differentiation are largely unknown.
Hypoxia can induce programmed (apoptotic) cell death in normal and neoplastic cells (101). Indeed, oncogenic transformation of cells (e.g., transfection with human papillomavirus E6/E7 genes or c-myc genes) increases their susceptibility to hypoxia-induced apoptosis (23). The level of p53 in cells increases under hypoxic conditions, and the increased level of p53 induces apoptosis by a pathway involving Apaf-1 and caspase-9 as downstream effectors (105). However, hypoxia also initiates p53-independent apoptosis pathways involving hypoxia-inducible factor-1 (HIF-1), genes of the BCL-2 family, and other unidentified genes (106,107). Below a critical energy state, hypoxia/anoxia may result in necrotic cell death, a phenomenon seen in many human tumors and experimental systems. Hypoxia-induced proteome changes, leading to cell cycle arrest, differentiation, apoptosis, and necrosis, may explain delayed recurrences, dormant micrometastases (108,109), and growth retardation in large tumor masses (110).
In contrast, hypoxia-induced proteome changes in tumor and/or stromal cells may promote tumor propagation by enabling the cells to adapt to nutritional deprivation or to escape their hostile environment. Hypoxia stimulates the transcription of glycolytic enzymes, glucose transporters (GLUT1 and GLUT3), angiogenic molecules, survival and growth factors (e.g., vascular endothelial growth factor [VEGF], angiogenin, platelet-derived growth factor-
, transforming growth factor-, and insulin-like growth factor-II), enzymes, proteins involved in tumor invasiveness (e.g., urokinase-type plasminogen activator), chaperones, and other resistance-related proteins (8,17,29,97,106,111–119). At the same time, hypoxia-induced inhibition of gene expression has been demonstrated for cell-surface integrins facilitating tumor cell detachment (120).
Many hypoxia-inducible genes are controlled by a common transcription factor, HIF-1, composed of two subunits, HIF-1
and HIF-1 (121). Increased concentrations of HIF-1 in the proteome of a hypoxic cell result from increased transcription of HIF-1 and HIF-1 genes and decreased HIF-1 protein degradation, an example of hypoxia-mediated posttranslational control (122–124). Jiang et al. (111) exposed human HeLa cells to concentrations of O2 between 0.125% and 20% (with 5% CO2 added and the remainder N2) and then analyzed HIF-1 expression as a function of intracellular O2 concentration. HIF-1 DNA-binding activity and the concentrations of HIF-1 protein and HIF-1 protein increased exponentially as cells were subjected to decreasing concentrations of O2, with a half-maximal response at about 10 mmHg. Hypoxia-induced HIF-1 activation can also result in an increased production of VEGF. To determine the reduced O2 concentration required to stimulate increased levels of VEGF messenger RNA (mRNA), Chiarotto and Hill (125) determined O2 concentrations in culture medium from cervical cancer cell lines SiHa, ME-180, or HeLa cells, under distinct boundary conditions, and defined the threshold for increasing the level of VEGF mRNA above baseline as O2 pressure of approximately 1 mmHg in the gassing mixture.
Nuclear factor 
B (NFB) is another transcriptional factor that can be activated by hypoxia (126). The threshold for activation of NFB in AG1522 cells occurs after 3 hours at an O2 partial pressure of about 15 mmHg (127). Thus, the critical O2 levels necessary for hypoxia-induced gene expression are probably in the range of 1–15 mmHg (Table 3 and see Fig. 4). Below these levels, mRNA levels often rise almost exponentially to a maximum value.
|
Whether the net phenotypic result of hypoxia-induced proteome changes of the tumor and stromal cells is neoplastic growth arrest (hypoxia/0 phenotype), growth impairment (hypoxia/– phenotype), or promotion through local, perifocal, regional, or distant tumor propagation (hypoxia/+ phenotype) may be determined by the genomic state, the degree of hypoxia, and microenvironmental epigenetic factors, in addition to hypoxia. Genomic changes in neoplastic cells that reduce the potential for cell cycle arrest, differentiation, and apoptosis may favor hypoxia-associated mechanisms that promote tumor growth and dissemination, such as stress adaptation, anaerobic metabolism, angiogenesis, tumor cell detachment and subsequent adhesion, tissue remodeling, and migration (Fig. 2
). |
HYPOXIA-MEDIATED MALIGNANT PROGRESSION |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
By clinical definition, malignant progression of a neoplasm means the increasing probability of local spread (through direct invasion of neighboring tissues and organs), perifocal spread (through migration of single neoplastic cells and microfoci into the interstitial space, lymphatic space involvement, and perineural invasion), regional spread (through metastases to the lymph nodes), and distant spread (through hematogenous metastases or dissemination into body cavities, such as the peritoneum and pleura), as well as the increasing resistance toward nonsurgical therapy concomitant with primary tumor growth. Clinical progression of a malignant tumor is a consequence of 1) an increasing neoplastic cell load, 2) microenvironment-induced (epigenetic) phenotypic changes in neoplastic and stromal cells, and 3) genotypic changes and clonal selection of neoplastic cells (135). Evidence is accumulating that hypoxia not only induces proteome changes influencing tumor propagation but also drives malignant progression through transient and persistent genomic changes in neoplastic cells (18,19,29,133–136). Hypoxia (with or without reoxygenation) promotes genomic instability (through point mutations, gene amplification, and chromosomal rearrangements) and may unveil pre-existing cryptic genetic variations (which are suppressed by chaperones in cells not experiencing permanent stress), thus increasing the number of genetic variants. Concomitantly, hypoxia exerts a strong selection pressure (Fig. 3
).
|
The importance of the hypoxia-mediated clonal expansion of tumor cells with diminished apoptotic potential has been demonstrated both experimentally and clinically (18,22,23). The increasing inability of tumor cells to activate apoptotic pathways can explain many of the clinical consequences of malignant progression, such as locoregional and distant tumor propagation and resistance to nonsurgical therapy. Survival and proliferation of occult perifocal tumor cells with diminished apoptotic potential, located in hypoxic surgical scars, appear to be major pathogenetic events in the formation of local recurrences, despite complete surgical resection of solid neoplasms with microscopically tumor-free resection margins (R0 resection; Höckel M: unpublished results).
In most investigations of hypoxia-induced genomic changes, transformed cells were incubated at almost zero O2 partial pressure and then reoxygenated at atmospheric O2 partial pressure. Rice et al. (29) demonstrated that, after incubating Chinese hamster ovary cells for up to 72 hours in less than 10 parts per million (ppm) of O2, the dihydrofolate reductase gene was amplified, which led to increased methotrexate resistance. By incubating murine cells under similar conditions, Young et al. (19) observed that DNA overreplication transiently enhanced the formation of experimental metastases. To induce the transformation of a benign B16 melanoma cell phenotype to a malignant phenotype, Stackpole et al. (137) incubated monolayers of cells for 48 hours in an O2-depleted medium. After 24 hours, these cultures were severely hypoxic (<50 ppm of O2). Russo and co-workers (134,136) observed DNA breakage resulting from activation of an endogenous endonuclease in immortal rat embryo fibroblasts cultured under anoxic conditions for up to 24 hours. Reynolds et al. (133) used a mouse tumor cell line carrying a chromosomally based 
phage shuttle vector for reporting mutations. After exposing these cells to an O2 partial pressure of less than 1 mmHg for 4 hours, they detected a mutation rate that was 3.4-fold higher than the rate in similar cells cultured under standard atmospheric conditions. Giaccia and colleagues (22,23,97) used an elegant procedure to select transformed cells with reduced apoptotic potential. Specifically, they cultured transformed mouse embryonic fibroblasts and transformed human cervical epithelial cells under a reduced O2 partial pressure of less than 1 mmHg for 48 hours, followed by up to seven reoxygenation treatments. As a rule, hypoxia-induced genomic changes are detectable at an O2 partial pressure of less than 1 mmHg, which is approximately one order of magnitude lower than the O2 partial pressures associated with proteome changes (Table 3 and Fig. 4).
Hypoxia-mediated clonal selection of neoplastic cells with persistent genomic changes leading, inter alia, to apoptotic insensitivity and increased angiogenic potential stabilizes and further aggravates tumor hypoxia, which in turn promotes malignant progression. Thus, hypoxia is involved in a vicious circle that is regarded as a fundamental biologic mechanism of the malignant disease, once cellular proliferation has been deregulated [(11,14) and Fig. 3].
|
TUMOR HYPOXIA AND TREATMENT RESISTANCE |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
Tumor hypoxia may present a severe problem for radiation therapy (x- and
-radiation), because radiosensitivity is progressively limited when the O2 partial pressure in a tumor is less than 25–30 mmHg (Table 3 and Fig. 4). Hypoxia-associated resistance to photon radiotherapy is multifactorial. The presence of molecular oxygen increases DNA damage through the formation of oxygen free radicals, which occurs primarily after the interaction of radiation with intracellular water (2). Thus, because of this so-called "oxygen enhancement effect," the radiation dose required to achieve the same biologic effect is three times higher in the absence of oxygen than in the presence of normal levels of oxygen (1–3). Evidence suggests that hypoxia-induced proteome and genome changes may also have a substantial impact on radioresistance by increasing the levels of heat shock proteins or by increasing the number of cells in a tumor with diminished apoptotic potential or increased proliferation potential (18,22,23), both of which have been linked to radioresistance (24,25). Oxygen dependency has been documented for a number of anticancer agents (e.g., cyclophosphamide, carboplatin, and doxorubicin) under in vitro and in vivo conditions (138,139). However, these investigations have been qualitative, and clear hypoxic thresholds for O2-dependent anticancer agents are still not available, although they presumably exist for each agent. Thus, additional research is necessary to provide quantitative data on hypoxia-induced chemoresistance, although this information may be difficult to obtain under in vivo conditions. Multiple mechanisms are probably also involved in the hypoxia-induced resistance to chemotherapeutic agents, including an inhibition of cell proliferation (140), a hypoxia-induced decreased cytotoxicity of some agents (98,138,141), and tissue acidosis, which is often observed in hypoxic tumors with a high glycolytic rate (142). Furthermore, hypoxic stress proteins and the loss of apoptotic potential can impart resistance to certain chemotherapeutic drugs (26–29,112,114,143).
Photodynamic therapy-mediated cell death requires the presence of oxygen, a photosensitizing drug, and light of the appropriate wavelength, both in vitro and in vivo [for a review, see (144)]. Reports (129,145), however, vary greatly on the extent to which photodynamic therapy with hematoporphyrin derivatives is dependent on oxygen. Cells were not killed under anoxic conditions. The critical threshold below which progressively reduced cell death was observed varied from 15 to 35 mmHg (129–131), probably because of the reduced production of singlet oxygen (1O2) species and different sensitivities to the treatment in different cell lines (Table 3 and Fig. 4). Considering the reduced effectiveness of photodynamic agents at lower O2 partial pressures, the rapid induction of tumor hypoxia by photodynamic therapy itself—either as a consequence of a photodynamic therapy-induced decrease in blood flow or as a result of oxygen consumption by the photodynamic therapy process itself—has to be considered under in vivo conditions, since it may mean that this therapy is self-limiting (129,132,146). Photodynamic therapy involving prodrugs, such as aminolevulinic acid, may be further limited because conversion of the prodrug to the active photosensitizer appears to be less effective under hypoxic conditions.
Studies of cells in vitro have identified several factors that can influence the effect of hyperthermia on cell survival. Cell lines can vary substantially in their intrinsic heat sensitivity. In addition, cell cycle position, intracellular pH, nutrient deprivation, and ATP depletion can affect cell survival after a heat treatment (147,148). At 43 °C hyperthermia, hypoxia per se may not cause cell death as long as concomitant changes in the nutritional and/or bioenergetic status of the cells do not occur (149).
Finally, tumor hypoxia can dramatically alter the potency of cytokines (interferon gamma and tumor necrosis factor-) and alter interleukin 2-induced activation of lymphokine-activated killer cells [reviewed in (128)]. The potency of treatment started to decrease at O2 partial pressures of less than approximately 35 mmHg (Table 3 and Fig. 4).
|
TUMOR HYPOXIA AS AN ADVERSE PROGNOSTIC FACTOR |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
Gatenby et al. (150) used polarographic electrodes to investigate the oxygenation status of advanced head and neck carcinomas and, thus, to our knowledge, were the first to report substantial differences in O2 partial pressures in tumors of patients who responded to radiotherapy versus tumors of those who did not. After a new generation of polarographic O2 sensors was introduced in 1989, a prospective clinical trial was initiated in which the prognostic relevance of O2 partial pressures in advanced cancers of the uterine cervix was investigated (11,14,151,152). An interim evaluation in 1991 found that a median O2 partial pressure of 10 mmHg appeared to be a cutoff level to distinguish between hypoxic cervical cancers with poor prognosis and less hypoxic cervical cancers with statistically significantly better prognosis. The study also demonstrated that tumor oxygenation was independent of various patient and tumor characteristics, including patient age, menopausal status and parity, International Federation of Gynecology and Obstetrics (FIGO) stage, clinical tumor size, histopathology, and grade of malignancy. A Kaplan–Meier life-table analysis showed statistically significantly shorter survival and recurrence-free survival for patients with hypoxic tumors. The results were consistent with the hypothesis that radiobiologically hypoxic tumors (i.e., tumors with a reduced radiosensitivity at critically low O2 levels) are less curable. However, other mechanisms of treatment failure, such as increased locoregional and distant tumor propagation, could not be excluded (151). By the end of 1995, 103 patients with advanced cancers of the uterine cervix had entered the study. From a histopathologic examination of the surgical specimens obtained from 47 patients during radical tumor resection, hypoxic tumors had larger extensions, more frequent (occult) parametrial spread, and more lymph-vascular space involvement than nonhypoxic tumors of the same clinical stage and size. Probabilities of 5-year overall and disease-free survival calculated for patients who underwent standard primary treatment for cure were again statistically significantly lower for those with hypoxic tumors than for those with nonhypoxic tumors of similar clinical stage and size. Cox regression analysis revealed tumor oxygenation as the strongest independent prognostic factor, followed by FIGO stage (11). Of special interest was the fact that the disadvantage in outcome for patients with hypoxic tumors was independent of the mode of primary treatment (radiation therapy or radical surgery). This finding led to the hypothesis that tumor hypoxia was associated with malignant progression in advanced cancer of the uterine cervix and that hypoxia not only may counteract O2-dependent forms of therapy but also may advance tumor progression per se irrespective of treatment [(11) and Table 4
].
|
More recently, Fyles et al. (157) also determined whether the pretreatment oxygenation status of tumors could predict disease-free survival by assessing data for 74 patients with cervical cancer who were treated with radiation. There was clear evidence that hypoxia (defined as the fraction of measured O2 partial pressures of <5 mmHg) is a statistically significant adverse prognostic factor of disease-free survival. Furthermore, Knocke et al. (154) confirmed the prognostic relevance of pretreatment tumor oxygenation status by studying 51 patients with cancer of the uterine cervix who were treated with primary radiation (Table 4
). Recently, Sundfor et al. (158) also reported a poor outcome associated with low oxygen tensions in 40 advanced squamous cell carcinomas of the uterine cervix.
In local recurrences of cervical cancer, oxygenation levels of the recurrent tumor were generally lower than levels in the primary tumors of comparable mass. In the cohort of patients with recurrent tumors, oxygenation measurements provided additional prognostic information. Patients with tumors that had a median O2 partial pressure of less than 4 mmHg had a statistically significantly shorter median survival time than those with median O2 partial pressure of 4 mmHg or more [Table 4 and (14)].
The pretreatment tumor oxygenation status was also assessed in patients with soft-tissue sarcomas (12,153,155,159,160). In these patients, the more hypoxic tumors were associated with a poorer survival when compared with normoxic tumors resulting from local treatment failure or distant metastases (Table 4).
In a study on the association between the tissue oxygenation status and the radiation response in lymph node metastases of squamous cell carcinomas of the head and neck, Nordsmark et al. (156) showed that the most hypoxic tumors had statistically significantly lower locoregional tumor control than well-oxygenated tumors. Cox multiple regression analysis found that an O2 partial pressure of 2.5 mmHg or less was the strongest independent variable for prediction of a response to radiation therapy, when the end point was tumor control at the site where the O2 partial pressure was measured. Brizel et al. (20,155) also showed that tumor hypoxia appears to adversely affect the prognosis of patients with primary and metastatic squamous cell carcinomas of the head and neck (Table 4).
|
HOW CAN THE TERM "TUMOR HYPOXIA" BE USED APPROPRIATELY? |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
By the definition and criteria presented in this review, there is clear evidence that the range of hypoxia in malignant tumors can vary widely. Critical O2 levels (hypoxic thresholds) characterize the upper limit of the hypoxic range below which activities and functions progressively become restricted. These O2 levels can encompass O2 partial pressures from 35 mmHg (start of reduced cell death in conventional photodynamic therapy or restricted efficacy of some immunotherapies) to 0.02 mmHg (below this level, cytochromes aa3 and c are no longer fully oxidized) with all other critical O2 levels for specific cellular functions or activities distributed in between (Fig. 4
). We, therefore, recommend that only data describing defined functions or activities of tumor cells or characteristics of tumors be compared. Because critical O2 levels of different parameters or reactions can vary substantially, we recommend that only results from assays describing the same biologic parameter (e.g., radiation sensitivity) be tested for correlation. Otherwise, pseudocorrelations may be misinterpreted as real biologic interrelationships.
|
NOTES |
|---|
Supported by a grant from the Deutsche Krebshilfe (70–1920-Va 2).
We thank Dr. Debra Kelleher for her valuable input during manuscript preparation.
|
REFERENCES |
|---|
|
TopNotesAbstractIntroductionDefinition and Causative...Metabolic Hypoxia in Solid...Methods for Detection of...Hypoxia-Mediated Proteome...Hypoxia-Mediated Malignant...Tumor Hypoxia and Treatment...Tumor Hypoxia as an...How Can the Term...References |
|---|
1 Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638–48.
2 Hall EJ, editor. Radiobiology for the radiologist. 4th ed. Philadelphia (PA): Lippincott; 1994.
3 Hill RP. Cellular basis of radiotherapy. In: Tannock IF, Hill RP, editors. The basic science of oncology. 2nd ed. New York (NY): McGraw-Hill; 1992. p. 259–75.
4 Vaupel P, Kelleher DK, editors. Tumor hypoxia: pathophysiology, clinical significance and therapeutic perspectives. Stuttgart (Germany): Wissenschaftliche Verlagsgesellschaft; 1999.
5 Molls M, Vaupel P, editors. Blood perfusion and microenvironment of human tumors. Implications for clinical radiooncology. Berlin and Heidelberg (Germany) and New York (NY): Springer; 2000.
6 Raleigh JA, editor. Hypoxia and Its Clinical Significance. Semin Radiat Oncol 1996;6:1–70.[CrossRef][Web of Science][Medline]
7
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408–16.
8 Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000;35:71–103.[CrossRef][Web of Science][Medline]cancerlit;20279498
9
Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474–80.
10 Sutherland RM. Tumor hypoxia and gene expression—implications for malignant progression and therapy. Acta Oncol 1998;37:567–74.[CrossRef][Web of Science][Medline]cancerlit;99075658
11
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–15.
12
Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Ean JM, Prosnitz LR, et al. Tumor oxygenation predicts the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941–3.
13 Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 1998;78:822–7.[Web of Science][Medline]cancerlit;98414240
14 Hockel M, Schlenger K, Hockel S, Aral B, Schaffer U, Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998;79:365–9.[CrossRef][Web of Science][Medline]cancerlit;98363108
15
Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000;60:916–21.
16 Cuvier C, Jang A, Hill RP. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 1997;15:19–25.[CrossRef][Web of Science][Medline]cancerlit;97162115
17 Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 1999;80:617–23.[CrossRef][Web of Science][Medline]cancerlit;99131865
18
Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525–8.
19
Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A 1988;85:9533–7.
20 Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285–9.[CrossRef][Web of Science][Medline]cancerlit;97369873
21 Jang A, Hill RP. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin Exp Metastasis 1997;15:469–83.[CrossRef][Web of Science][Medline]cancerlit;97388416
22 Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88–91.[CrossRef][Medline]cancerlit;96135141
23
Kim CY, Tsai MH, Osmanian C, Graeber TG, Lee JE, Giffard RG, et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 1997;57:4200–04.
24 Samali A, Cotter TG. Heat shock proteins increase resistance to apoptosis. Exp Cell Res 1996;223:163–70.[CrossRef][Web of Science][Medline]cancerlit;96209639
25 Zhivotovsky B, Joseph B, Orrenius S. Tumor radiosensitivity and apoptosis. Exp Cell Res 1999;248:10–7.[CrossRef][Web of Science][Medline]cancerlit;99196909
26
Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996;56:1374–81.
27 Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662–8.[CrossRef][Web of Science][Medline]cancerlit;99297915
28 Hickman JA, Potten CS, Merritt AJ, Fisher TC. Apoptosis and cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci 1994;345:319–25.[Web of Science][Medline]cancerlit;95148704
29
Rice GC, Hoy C, Schimke RT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 1986;83:5978–82.
30 West JB. Respiratory physiology—the essentials. 6th ed. Baltimore (MD), London (U.K.), and Los Angeles (CA): Williams & Wilkins; 1999.
31 Boyer PD, Chance B, Ernster L, Mitchell P, Racker E, Slater EC. Oxidative phosphorylation and photophosphorylation. Annu Rev Biochem 1977;46:955–1026.[CrossRef][Web of Science][Medline]
32 Honig CR. Modern cardiovascular physiology. 2nd ed. Boston (MA) and Toronto (ON, Canada): Little and Brown; 1988.
33 Zander R, Vaupel P. Proposal for using a standardized terminology on oxygen transport to tissue. Adv Exp Med Biol 1985;191:965–70.[Web of Science][Medline]
34
Glossary on respiration and gas exchange. J Appl Physiol 1973;34:549–58.
35
Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449–65.
36
Vaupel P, Fortmeyer HP, Runkel S, Kallinowski F. Blood flow, oxygen consumption, and tissue oxygenation of human breast cancer xenografts in nude rats. Cancer Res 1987;47:3496–503.
37
Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, et al. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 1989;49:3759–64.
38 Vaupel P, Schaefer C, Okunieff P. Intracellular acidosis in murine fibrosarcomas coincides with ATP depletion, hypoxia, and high levels of lactate and total Pi. NMR Biomed 1994;7:128–36.[Web of Science][Medline]cancerlit;94361915
39 Kruger W, Mayer WK, Schaefer C, Stohrer M, Vaupel P. Acute changes of systemic parameters in tumour-bearing rats, and of tumour glucose, lactate, and ATP levels upon local hyperthermia and/or hyperglycaemia. J Cancer Res Clin Oncol 1991;117:409–15.[CrossRef][Web of Science][Medline]cancerlit;91365799
40 Vaupel P. Physiological properties of malignant tumours. NMR Biomed 1992;5:220–5.[Web of Science][Medline]cancerlit;93081230
41 Gerweck LE, Seneviratne T, Gerweck KK. Energy status and radiobiological hypoxia at specified oxygen concentrations. Radiat Res 1993;135:69–74.[CrossRef][Web of Science][Medline]
42 Marshall RS, Koch CJ, Rauth AM. Measurement of low levels of oxygen and their effect on respiration in cell suspensions maintained in an open system. Radiat Res 1986;108:91–101.[CrossRef][Web of Science][Medline]
43 Starlinger H, Lubbers DW. Methodical studies on the polarographic measurement of respiration and "critical oxygen pressure" in mitochondria and isolated cells with membrane-covered platinum electrodes. Pflugers Arch 1972;337:19–28.[CrossRef][Web of Science][Medline]
44 Froese G. The respiration of ascites tumour cells at low oxygen concentrations. Biochim Biophys Acta 1962;57:509–19.[Medline]
45
Robiolio M, Rumsey WL, Wilson DF. Oxygen diffusion and mitochondrial respiration in neuroblastoma cells. Am J Physiol 1989;256:C1207–13.
46
Wilson DF, Rumsey WL, Green TJ, Vanderkooi JM. The oxygen dependence of mitochondrial oxidative phosphorylation measured by a new optical method for measuring oxygen concentration. J Biol Chem 1988;263:2712–8.
47 Chance B, Oshino N, Sugano T, Mayevsky A. Basic principles of tissue oxygen determination from mitochondrial signals. Adv Exp Med Biol 1973;37A:277–92.
48 Groebe K. Impact of anemia on the oxygenation status of tumors: a theoretical study. In: Vaupel P, Kelleher DK, editors. Tumor hypoxia: pathophysiology, clinical significance and therapeutic perspectives. Stuttgart (Germany): Wissenschaftliche Verlagsgesellschaft; 1999. p. 75–82.
49 Vaupel PW. Blood flow, oxygenation, tissue pH distribution and bioenergetic status of tumors. Berlin (Germany): Ernst Schering Research Foundation, Lecture 23; 1994.
50 Schaefer C, Okunieff P, Vaupel P. Oxygenation and bioenergetic status of murine fibrosarcomas. Adv Exp Med Biol 1992;317:161–7.[Medline]cancerlit;93166984
51 Mueller-Klieser W, Schlenger KH, Walenta S, Gross M, Karbach U, Hoeckel M et al. Pathophysiological approaches to identifying tumor hypoxia in patients. Radiother Oncol 1991;20 Suppl 1:21–8.cancerlit;91212626
52 Chapman JD. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother Oncol 1991;20 Suppl 1:13–9.cancerlit;91212622
53 Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19–20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res 1993;136:422–34.[Web of Science][Medline]cancerlit;94105384
54 Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229–37.[CrossRef][Web of Science][Medline]cancerlit;98232328
55 Kallinowski F, Zander R, Hoeckel M, Vaupel P. Tumor tissue oxygenation as evaluated by computerized pO2-histography. Int J Radiat Oncol Biol Phys 1990;19:953–61.[Web of Science][Medline]cancerlit;91008570
56
Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991;51:3316–22.
57
Hockel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 1991;51:6098–102.
58 Collingridge DR, Young WK, Vojnovic B, Wardman P, Lynch EM, Hill SA, et al. Measurement of tumor oxygenation: a comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat Res 1997;147:329–34.[Web of Science][Medline]cancerlit;97205175
59 Griffiths JR, Robinson SP. The OxyLite: a fibre-optic oxygen sensor. Br J Radiol 1999;72:627–30.[Web of Science][Medline]cancerlit;20089443
60 Swartz HM, Bacic G, Friedman B, Goda F, Grinberg O, Hoopes PJ, et al. Measurements of pO2 in vivo, including human subjects, by electron paramagnetic resonance. Adv Exp Med Biol 1994;361:119–28.[Medline]cancerlit;95321133
61
Halpern HJ, Yu C, Peric M, Barth E, Grdina DJ, Teicher BA. Oxymetry deep in tissues with low-frequency electron paramagnetic resonance. Proc Natl Acad Sci U S A 1994;91:13047–51.
62 Wendling P, Manz R, Thews G, Vaupel P. Heterogeneous oxygenation of rectal carcinomas in humans: a critical parameter for preoperative irradiation? Adv Exp Med Biol 1984;180:293–300.[Web of Science][Medline]cancerlit;85195625
63 Mueller-Klieser W, Vaupel P, Manz R, Schmidseder R. Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int J Radiat Oncol Biol Phys 1981;7:1397–404.[Web of Science][Medline]cancerlit;82097756
64 Rofstad EK, Fenton BM, Sutherland RM. Intracapillary HbO2 saturations in murine tumours and human tumour xenografts measured by cryospectrophotometry: relationship to tumour volume, tumour pH and fraction of radiobiologically hypoxic cells. Br J Cancer 1988;57:494–502.[Web of Science][Medline]cancerlit;88281362
65
Fenton BM, Rofstad EK, Degner FL, Sutherland RM. Cryospectrophotometric determination of tumor intravascular oxyhemoglobin saturations: Dependence on vascular geometry and tumor growth. J Natl Cancer Inst 1988;80:1612–9.
66 Sevick EM, Chance B, Leigh J, Nioka S, Maris M. Quantitation of time- and frequency-resolved optical spectra for the determination of tissue oxygenation. Anal Biochem 1991;195:330–51.[CrossRef][Web of Science][Medline]
67 Hull EL, Conover DL, Foster TH. Carbogen-induced changes in rat mammary tumour oxygenation reported by near infrared spectroscopy. Br J Cancer 1999;79:1709–16.[CrossRef][Web of Science][Medline]cancerlit;99221122
68
Wilson DF, Cerniglia GJ. Localization of tumors and evaluation of their state of oxygenation by phosphorescence imaging. Cancer Res 1992;52:3988–93.
69 Robinson SP, Collingridge DR, Howe FA, Rodrigues LM, Chaplin DJ, Griffiths JR. Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed 1999;12:98–106.[CrossRef][Web of Science][Medline]cancerlit;99319977
70 Stubbs M, Griffiths JR. Monitoring cancer by magnetic resonance. Br J Cancer 1999;80 Suppl 1:86–94.cancerlit;99394642
71 McCoy CL, McIntyre DJ, Robinson SP, Aboagye EO, Griffiths JR. Magnetic resonance spectroscopy and imaging methods for measuring tumour and tissue oxygenation. Br J Cancer 1996;74 Suppl 27:S226–31.
72 Le D, Mason RP, Hunjan S, Constantinescu A, Barker BR, Antich PP. Regional tumor oxygen dynamics: 19F PBSR EPI of hexafluorobenzene. Magn Reson Imaging 1997;15:971–81.[CrossRef][Web of Science][Medline]cancerlit;97463432
73 van der Sanden BP, Heerschap A, Simonetti AW, Rijken PF, Peters HP, Stuben G, et al. Characterization and validation of noninvasive oxygen tension measurements in human glioma xenografts by 19F-MR relaxometry. Int J Radiat Oncol Biol Phys 1999;44:649–58.[CrossRef][Web of Science][Medline]cancerlit;99276052
74 Hunjan S, Mason RP, Constantinescu A, Peschke P, Hahn EW, Antich PP. Regional tumor oximetry: 19F NMR spectroscopy of hexafluorobenzene. Int J Radiat Oncol Biol Phys 1998;41:161–71.[CrossRef][Web of Science][Medline]cancerlit;98248345
75 Fishman JE, Joseph PM, Carvlin MJ, Saadi-Elmandjra M, Mukherji B, Sloviter HA. In vivo measurements of vascular oxygen tension in tumors using MRI of a fluorinated blood substitute. Invest Radiol 1989;24:65–71.[CrossRef][Web of Science][Medline]cancerlit;89138936
76 Mason RP, Antich PP, Babcock EE, Constantinescu A, Peschke P, Hahn EW. Non-invasive determination of tumor oxygen tension and local variation with growth. Int J Radiat Oncol Biol Phys 1994;29:95–103.[Web of Science][Medline]cancerlit;94230084
77 Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1991;22:199–212.
78 Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995;33:391–8.[CrossRef][Web of Science][Medline]cancerlit;95403208
79 Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417–28.[CrossRef][Web of Science][Medline]cancerlit;97047547
80
Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133–7.
81 Parliament M, Urtasun R. Misonidazole labeling as a marker of cellular hypoxia. In: Molls M, Vaupel P, editors. Blood perfusion and microenvironment of human tumors. Implications for clinical radiooncology. Berlin and Heidelberg (Germany) and New York (NY): Springer; 2000. p. 89–99.
82
Groshar D, McEwan AJ, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med 1993;34:885–8.
83 Parliament MB, Chapman JD, Urtasun RC, McEwan AJ, Golberg LE, Mercer JR, et al. Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992;65:90–5.[Web of Science][Medline]cancerlit;92126509
84 Urtasun RC, Chapman JD, Raleigh JA, Franko AJ, Koch CJ. Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys 1986;12:1263–7.[Web of Science][Medline]cancerlit;86303826
85 Cline JM, Thrall DE, Rosner GL, Raleigh JA. Distribution of the hypoxia marker CCI-103F in canine tumors. Int J Radiat Oncol Biol Phys 1994;28:921–33.[Web of Science][Medline]cancerlit;94186394
86 Cline JM, Thrall DE, Page RL, Raleigh JA. Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours. Br J Cancer 1990;62:925–31.[Web of Science][Medline]cancerlit;91077263
87 Gross MW, Karbach U, Groebe K, Franko AJ, Mueller-Klieser W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer 1995;61:567–73.[Web of Science][Medline]cancerlit;95279006
88 Raleigh JA, Dewhirst MW, Thrall DE. Measuring Tumor Hypoxia. Semin Radiat Oncol 1996;6:37–45.[CrossRef][Web of Science][Medline]
89 Azuma C, Raleigh JA, Thrall DE. Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat Res 1997;148:35–42.[CrossRef][Web of Science][Medline]cancerlit;97359700
90 Kennedy AS, Raleigh JA, Perez GM, Calkins DP, Thrall DE, Novotny DB, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 1997;37:897–905.[CrossRef][Web of Science][Medline]cancerlit;97275073
91
Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 1993;53:5721–6.
92 Lee J, Siemann DW, Koch CJ, Lord EM. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer 1996;67:372–8.[CrossRef][Web of Science][Medline]cancerlit;96321022
93
Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996;56:405–11.
94 Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC Jr, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 1998;71:270–7.[CrossRef][Web of Science][Medline]cancerlit;99045535
95 Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995;72:869–74.[Web of Science][Medline]cancerlit;96003567
96 Hodgkiss RJ, Webster L, Wilson GD. Measurement of hypoxia in vivo using a 2-nitroimidazole (NITP). Adv Exp Med Biol 1997;428:61–7.[Web of Science][Medline]cancerlit;98161010
97 Giaccia AJ. Hypoxic Stress Proteins: Survival of the Fittest. Semin Radiat Oncol 1996;6:46–58.[CrossRef][Web of Science][Medline]
98 Durand RE. Keynote address: the influence of microenvironmental factors on the activity of radiation and drugs. Int J Radiat Oncol Biol Phys 1991;20:253–8.[Web of Science][Medline]cancerlit;91123123
99 Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313–41.[CrossRef][Web of Science][Medline]cancerlit;87188056
100 Haroon ZA, Raleigh JA, Greenberg CS, Dewhirst MW. Early wound healing exhibits cytokine surge without evidence of hypoxia. Ann Surg 2000;231:137–47.[CrossRef][Web of Science][Medline]cancerlit;20100069
101 Riva C, Chauvin C, Pison C, Leverve X. Cellular physiology and molecular events in hypoxia-induced apoptosis. Anticancer Res 1998;18:4729–36.[Web of Science][Medline]
102 Amellem O, Loffler M, Pettersen EO. Regulation of cell proliferation under extreme and moderate hypoxia: the role of pyrimidine (deoxy) nucleotides. Br J Cancer 1994;70:857–66.[Web of Science][Medline]cancerlit;95034048
103 Koch CJ, Kruuv J, Frey HE. The effect of hypoxia on the generation time of mammalian cells. Radiat Res 1973;53:43–8.[CrossRef][Web of Science][Medline]
104 Pettersen EO, Lindmo T. Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia. Br J Cancer 1983;48:809–17.[Web of Science][Medline]
105
Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999;284:156–9.
106 Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68–72.[CrossRef][Web of Science][Medline]cancerlit;99198474
107 Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsujimoto Y. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature 1995;374:811–3.[CrossRef][Medline]cancerlit;95240711
108 Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149–53.[CrossRef][Web of Science][Medline]cancerlit;96071395
109
Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994;86:45–8.
110
Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991;51:2–4.
111
Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996;271:C1172–80.
112 Mattern J, Kallinowski F, Herfarth C, Volm M. Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Int J Cancer 1996;67:20–3.[CrossRef][Web of Science][Medline]cancerlit;96279801
113 Sanna K, Rofstad EK. Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 1994;58:258–62.[Web of Science][Medline]cancerlit;94299319
114
Ausserer WA, Bourrat-Floeck B, Green CJ, Laderoute KR, Sutherland RM. Regulation of c-jun expression during hypoxic and low-glucose stress. Mol Cell Biol 1994;14:5032–42.
115
Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ Jr, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994;14:6264–77.
116 Laderoute KR, Grant TD, Murphy BJ, Sutherland RM. Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. Int J Cancer 1992;52:428–32.[Web of Science][Medline]cancerlit;93014347
117 Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843–5.[CrossRef][Medline]cancerlit;93063296
118
Wilson RE, Keng PC, Sutherland RM. Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia. J Natl Cancer Inst 1989;81:1235–40.
119
Hartmann A, Kunz M, Kostlin S, Gillitzer R, Toksoy A, Brocker EB, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999;59:1578–83.
120 Hasan NM, Adams GE, Joiner MC, Marshall JF, Hart IR. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer 1998;77:1799–805.[Web of Science][Medline]cancerlit;98330223
121
Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510–4.
122 Cockman ME, Maxwell PH, Ratcliffe PJ. The beta domain of pVHL is necessary for HIF-alpha regulation. In: Symposium on Tissue Hypoxia. London (U.K.): Academy of Pharmaceutical Scientists; 2000.
123
Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel– Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cu12. Mol Cell Biol 1998;18:732–41.
124 Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271–5.[CrossRef][Medline]cancerlit;99279691
125 Chiarotto JA, Hill RP. A quantitative analysis of the reduction in oxygen levels required to induce up-regulation of vascular endothelial growth factor (VEGF) mRNA in cervical cancer cell lines. Br J Cancer 1999;80:1518–24.[CrossRef][Web of Science][Medline]cancerlit;99334877
126
Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of nuclear factor B through the phosphorylation of IB on tyrosine residues. Cancer Res 1994;54:1425–30.
127 Brown JM, Giaccia AJ. Tumour hypoxia: the picture has changed in the 1990s. Int J Radiat Biol 1994;65:95–102.[Web of Science][Medline]cancerlit;94141365
128 Chaplin DJ, Horsman MR, Trotter MJ, Siemann DW. Therapeutic significance of microenvironmental factors. In: Molls M, Vaupel P, editors. Blood perfusion and microenvironment of human tumors. Implications for clinical radiooncology. Berlin and Heidelberg (Germany) and New York (NY): Springer; 2000. p. 133–43.
129
Henderson BW, Fingar VH. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res 1987;47:3110–4.
130
Mitchell JB, McPherson S, DeGraff W, Gamson J, Zabell A, Russo A. Oxygen dependence of hematoporphyrin derivative-induced photo-inactivation of Chinese hamster cells. Cancer Res 1985;45:2008–11.
131 Chapman JD, Stobbe CC, Arnfield MR, Santus R, Lee L, McPhee MS. Oxygen dependency of tumor cell killing in vitro by light-activated Photofrin II. Radiat Res 1991;126:73–9.[CrossRef][Web of Science][Medline]cancerlit;91212574
132
Chapman JD, McPhee MS, Walz N, Chetner MP, Stobbe CC, Soderlind K, et al. Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors. J Natl Cancer Inst 1991;83:1650–9.
133
Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996;56:5754–7.
134
Stoler DL, Anderson GR, Russo CA, Spina AM, Beerman TA. Anoxia-inducible endonuclease activity as a potential basis of the genomic instability of cancer cells. Cancer Res 1992;52:4372–8.
135 Cheng KC, Loeb LA. Genomic instability and tumor progression: mechanistic considerations. Adv Cancer Res 1993;60:121–56.[Web of Science][Medline]cancerlit;93111179
136
Russo CA, Weber TK, Volpe CM, Stoler DL, Petrelli NJ, Rodriguez-Bigas M, et al. An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Res 1995;55:1122–8.
137
Stackpole CW, Groszek L, Kalbag SS. Benign-to-malignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. J Natl Cancer Inst 1994;86: 361–7.
138
Teicher BA, Holden SA, al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaII murine fibrosarcoma. Cancer Res 1990;50:3339–44.
139
Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73–81.
140
Bedford JS, Mitchell JB. The effect of hypoxia on the growth and radiation response of mammalian cells in culture. Br J Radiol 1974;47:687–96.
141
Durand RE. The influence of microenvironmental factors during cancer therapy. In Vivo 1994;8:691–702.
142 Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984;2:343–66.[Web of Science][Medline]cancerlit;85114109
143 Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 1991;64:809–14.[Web of Science][Medline]cancerlit;92030950
144 Freitas I, Baronzio GF. Tumor hypoxia, reoxygenation and oxygenation strategies: possible role in photodynamic therapy. J Photochem Photobiol B 1991;11:3–30.[CrossRef][Medline]cancerlit;92166931
145
Moan J, Sommer S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. Cancer Res 1985;45:1608–10.
146 Bicher HI, Hetzel FW, Vaupel P, Sandhu TS. Microcirculation modifications by localized microwave hyperthermia and hematoporphyrin phototherapy. Bibl Anat 1981;20:628–32.
147 Song CW, Choi IB, Nah BS, Sahu SK, Osborn JL. Microvasculature and perfusion in normal tissues and tumors. In: Seegenschmiedt MH, Fessenden P, Vernon CC, editors. Medical radiology—diagnostic imaging and radiation oncology, thermoradiotherapy and thermochemotherapy. Berlin and Heidelberg (Germany) and New York (NY): Springer; 1995. p. 139–56.
148 Vaupel PW, Kelleher DK. Metabolic status and reaction to heat of normal and tumor tissue. In: Seegenschmiedt MH, Fessenden P, Vernon CC, editors. Medical radiology—diagnostic imaging and radiation oncology, thermoradiotherapy and thermochemotherapy. Berlin and Heidelberg (Germany) and New York (NY): Springer; 1995. p. 157–76.
149 Gerweck LE, Richards B, Jennings M. The influence of variable oxygen concentration on the response of cells to heat or X irradiation. Radiat Res 1981;85:314–20.[CrossRef][Web of Science][Medline]
150 Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831–8.[Web of Science][Medline]cancerlit;88197764
151 Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45–50.[CrossRef][Web of Science][Medline]cancerlit;93174029
152 Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and Radiation Response in Human Tumors. Semin Radiat Oncol 1996;6:3–9.[CrossRef][Web of Science][Medline]
153 Nordsmark M, Hoyer M, Keller J, Nielsen OS, Jensen OM, Overgaard J. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1996;35:701–8.[CrossRef][Web of Science][Medline]cancerlit;96305156
154 Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999;53:99–104.[CrossRef][Web of Science][Medline]cancerlit;20127551
155 Brizel DM. Human tumor oxygenation: The Duke University Medical Center experience. In: Vaupel P, Kelleher DK, editors. Tumor hypoxia. Pathophysiology, clinical significance and therapeutic perspectives. Stuttgart (Germany): Wissenschaftliche Verlagsgesellschaft; 1999. p. 29–38.
156 Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31–9.[Web of Science][Medline]cancerlit;97120694
157 Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149–56.[CrossRef][Web of Science][Medline]cancerlit;98455207
158 Sundfor K, Lyng H, Trope CG, Rofstad EK. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. Radiother Oncol 2000;54:101–7.[CrossRef][Web of Science][Medline]cancerlit;20173738
159 Nordsmark M, Hoyer M, Keller J, Jensen OM, Nielsen OS, Overgaard J. Predictive assays in radiotherapy, the Aarhus experience. Oxygenation, cell kinetics and 31P MR spectroscopy in human soft tissue sarcomas. Radiother Oncol 1996;46(suppl 1):S107.
160 Nordsmark M, Keller J, Hoyer M, Nielsen OS, Jensen OM, Overgaard J. Hypoxia in human soft tissue sarcomas associated with poor survival. Radiother Oncol 1998;48(suppl 1):S162.
161 Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000;76:589–605.[CrossRef][Web of Science][Medline]cancerlit;20322650
162 Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000;36:1649–60.
Manuscript received May 10, 2000; revised November 1, 2000; accepted November 30, 2000.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Sinha, S. Dutta, K. Datta, A. K. Ghosh, and D. Mukhopadhyay Von Hippel-Lindau Gene Product Modulates TIS11B Expression in Renal Cell Carcinoma: IMPACT ON VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN HYPOXIA J. Biol. Chem., November 20, 2009; 284(47): 32610 - 32618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Poomthavorn, S. H X Wong, S. Higgins, G. A Werther, and V. C Russo Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells Endocr. Relat. Cancer, September 1, 2009; 16(3): 991 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O.-Y. FU, M.-F. HOU, S.-F. YANG, S.-C. HUANG, and W.-Y. LEE Cobalt Chloride-induced Hypoxia Modulates the Invasive Potential and Matrix Metalloproteinases of Primary and Metastatic Breast Cancer Cells Anticancer Res, August 1, 2009; 29(8): 3131 - 3138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rapisarda, M. Hollingshead, B. Uranchimeg, C. A. Bonomi, S. D. Borgel, J. P. Carter, B. Gehrs, M. Raffeld, R. J. Kinders, R. Parchment, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition Mol. Cancer Ther., July 1, 2009; 8(7): 1867 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kudo, M. Ueda, Y. Kuge, T. Mukai, S. Tanaka, M. Masutani, Y. Kiyono, S. Kizaka-Kondoh, M. Hiraoka, and H. Saji Imaging of HIF-1-Active Tumor Hypoxia Using a Protein Effectively Delivered to and Specifically Stabilized in HIF-1-Active Tumor Cells J. Nucl. Med., June 1, 2009; 50(6): 942 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Paul, S. Teng, and P. T.K. Saunders A Single, Mild, Transient Scrotal Heat Stress Causes Hypoxia and Oxidative Stress in Mouse Testes, Which Induces Germ Cell Death Biol Reprod, May 1, 2009; 80(5): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Q. Brown, L. G. Wilke, J. Geradts, S. A. Kennedy, G. M. Palmer, and N. Ramanujam Quantitative Optical Spectroscopy: A Robust Tool for Direct Measurement of Breast Cancer Vascular Oxygenation and Total Hemoglobin Content In vivo Cancer Res., April 1, 2009; 69(7): 2919 - 2926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cannito, E. Novo, A. Compagnone, L. Valfre di Bonzo, C. Busletta, E. Zamara, C. Paternostro, D. Povero, A. Bandino, F. Bozzo, et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells Carcinogenesis, December 1, 2008; 29(12): 2267 - 2278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Komar, M. Seppanen, O. Eskola, P. Lindholm, T. J. Gronroos, S. Forsback, H. Sipila, S. M. Evans, O. Solin, and H. Minn 18F-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck Cancer J. Nucl. Med., December 1, 2008; 49(12): 1944 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Helczynska, A.-M. Larsson, L. Holmquist Mengelbier, E. Bridges, E. Fredlund, S. Borgquist, G. Landberg, S. Pahlman, and K. Jirstrom Hypoxia-Inducible Factor-2{alpha} Correlates to Distant Recurrence and Poor Outcome in Invasive Breast Cancer Cancer Res., November 15, 2008; 68(22): 9212 - 9220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Papadopoulos, S. Goel, M. Beeram, A. Wong, K. Desai, M. Haigentz, M. L. Milian, S. Mani, A. Tolcher, A. S. Lalani, et al. A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies Clin. Cancer Res., November 1, 2008; 14(21): 7110 - 7115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Lim, Y.-S. Chun, and J.-W. Park Hypoxia-Inducible Factor-1{alpha} Obstructs a Wnt Signaling Pathway by Inhibiting the hARD1-Mediated Activation of {beta}-Catenin Cancer Res., July 1, 2008; 68(13): 5177 - 5184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mayer, M. Hockel, A. Wree, C. Leo, L.-C. Horn, and P. Vaupel Lack of Hypoxic Response in Uterine Leiomyomas despite Severe Tissue Hypoxia Cancer Res., June 15, 2008; 68(12): 4719 - 4726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Spence, M. Muzi, K. R. Swanson, F. O'Sullivan, J. K. Rockhill, J. G. Rajendran, T. C.H. Adamsen, J. M. Link, P. E. Swanson, K. J. Yagle, et al. Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival Clin. Cancer Res., May 1, 2008; 14(9): 2623 - 2630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Shin, Y.-S. Chun, D. S. Lee, L. E. Huang, and J.-W. Park Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1 Blood, March 15, 2008; 111(6): 3131 - 3136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-S. Zhang, L. Eaton, E. R. Snyder, S. Houghtaling, J. B. Mitchell, M. Finegold, C. Van Waes, and M. Grompe Tempol Protects against Oxidative Damage and Delays Epithelial Tumor Onset in Fanconi Anemia Mice Cancer Res., March 1, 2008; 68(5): 1601 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Furuta, S. K. Pai, R. Zhan, S. Bandyopadhyay, M. Watabe, Y.-Y. Mo, S. Hirota, S. Hosobe, T. Tsukada, K. Miura, et al. Fatty Acid Synthase Gene Is Up-regulated by Hypoxia via Activation of Akt and Sterol Regulatory Element Binding Protein-1 Cancer Res., February 15, 2008; 68(4): 1003 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Albertella, P. M. Loadman, P. H. Jones, R. M. Phillips, R. Rampling, N. Burnet, C. Alcock, A. Anthoney, E. Vjaters, C. R. Dunk, et al. Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study Clin. Cancer Res., February 15, 2008; 14(4): 1096 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Hughes-Cassidy, J. Wong, D. Aguirre, A. D. Chavez, T. Wolfson, A. Gamst, and C. Sirlin Transient Homogeneously Enhancing Hepatic Masses: Can Size Predict Benignity? Am. J. Roentgenol., February 1, 2008; 190(2): 300 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Calvani, D. Trisciuoglio, C. Bergamaschi, R. H. Shoemaker, and G. Melillo Differential Involvement of Vascular Endothelial Growth Factor in the Survival of Hypoxic Colon Cancer Cells Cancer Res., January 1, 2008; 68(1): 285 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhu, L. Lu, W. Cai, X. Yang, C. Li, Z. Yang, W. Zhan, J.-x. Ma, and G. Gao Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis Mol. Cancer Ther., December 1, 2007; 6(12): 3297 - 3306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Kim, H. J. Shin, K.-Y. Jung, S.-K. Baek, B. K. Shin, J. Choi, B. S. Kim, S. W. Shin, Y. H. Kim, J. S. Kim, et al. Prognostic Value of Carbonic Anhydrase IX and Ki-67 Expression in Squamous Cell Carcinoma of the Tongue Jpn. J. Clin. Oncol., November 1, 2007; 37(11): 812 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-L. Sun, J.-M. Yuan, W. P. Koh, H.-P. Lee, and M. C. Yu Green tea and black tea consumption in relation to colorectal cancer risk: the Singapore Chinese Health Study Carcinogenesis, October 1, 2007; 28(10): 2143 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Endo, K. Murata, M. Mukai, O. Ishikawa, and M. Inoue Activation of Insulin-like Growth Factor Signaling Induces Apoptotic Cell Death Under Prolonged Hypoxia by Enhancing Endoplasmic Reticulum Stress Response Cancer Res., September 1, 2007; 67(17): 8095 - 8103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pandey, S. Heeger, and C. F. Lehner Rapid effects of acute anoxia on spindle kinetochore interactions activate the mitotic spindle checkpoint J. Cell Sci., August 15, 2007; 120(16): 2807 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Jung, H. S. Kim, C. S. Lee, D.-H. Park, Y.-N. Kim, M.-J. Lee, J. W. Lee, J.-W. Park, M.-S. Kim, S. K. Ye, et al. Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells Carcinogenesis, August 1, 2007; 28(8): 1780 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Merighi, A. Benini, P. Mirandola, S. Gessi, K. Varani, C. Simioni, E. Leung, S. Maclennan, P. G. Baraldi, and P. A. Borea Caffeine Inhibits Adenosine-Induced Accumulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Interleukin-8 Expression in Hypoxic Human Colon Cancer Cells Mol. Pharmacol., August 1, 2007; 72(2): 395 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wouters, B. Pauwels, F. Lardon, and J. B. Vermorken Review: Implications of In Vitro Research on the Effect of Radiotherapy and Chemotherapy Under Hypoxic Conditions Oncologist, June 1, 2007; 12(6): 690 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Frederiksen, R. Sullivan, L. R. Maxwell, S. K. Macdonald-Goodfellow, M. A. Adams, B. M. Bennett, D. R. Siemens, and C. H. Graham Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling Clin. Cancer Res., April 1, 2007; 13(7): 2199 - 2206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Lalani, S. E. Alters, A. Wong, M. R. Albertella, J. L. Cleland, and W. D. Henner Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2216 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rofstad, K. Galappathi, B. Mathiesen, and E.-B. M. Ruud Fluctuating and Diffusion-Limited Hypoxia in Hypoxia-Induced Metastasis Clin. Cancer Res., April 1, 2007; 13(7): 1971 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Veschini, D. Belloni, C. Foglieni, M. G. Cangi, M. Ferrarini, F. Caligaris-Cappio, and E. Ferrero Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib Blood, March 15, 2007; 109(6): 2565 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Maekawa, T. Shinagawa, Y. Sano, T. Sakuma, S. Nomura, K. Nagasaki, Y. Miki, F. Saito-Ohara, J. Inazawa, T. Kohno, et al. Reduced Levels of ATF-2 Predispose Mice to Mammary Tumors Mol. Cell. Biol., March 1, 2007; 27(5): 1730 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Hewitson, B. M. R. Lienard, M. A. McDonough, I. J. Clifton, D. Butler, A. S. Soares, N. J. Oldham, L. A. McNeill, and C. J. Schofield Structural and Mechanistic Studies on the Inhibition of the Hypoxia-inducible Transcription Factor Hydroxylases by Tricarboxylic Acid Cycle Intermediates J. Biol. Chem., February 2, 2007; 282(5): 3293 - 3301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Maher, M. Wangpaichitr, N. Savaraj, M. Kurtoglu, and T. J. Lampidis Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose Mol. Cancer Ther., February 1, 2007; 6(2): 732 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Maroni, P. Bendinelli, E. Matteucci, and M. A. Desiderio HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-{kappa}B Carcinogenesis, February 1, 2007; 28(2): 267 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yin, S. Kharbanda, and D. Kufe Mucin 1 Oncoprotein Blocks Hypoxia-inducible Factor 1{alpha} Activation in a Survival Response to Hypoxia J. Biol. Chem., January 5, 2007; 282(1): 257 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Martinive, F. Defresne, C. Bouzin, J. Saliez, F. Lair, V. Gregoire, C. Michiels, C. Dessy, and O. Feron Preconditioning of the Tumor Vasculature and Tumor Cells by Intermittent Hypoxia: Implications for Anticancer Therapies Cancer Res., December 15, 2006; 66(24): 11736 - 11744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maity and C. Koumenis HIF and MIF--a nifty way to delay senescence? Genes & Dev., December 15, 2006; 20(24): 3337 - 3341. [Full Text] [PDF]
|
|
|
|
|
|
H. Yasuda, K. Nakayama, M. Watanabe, S. Suzuki, H. Fuji, S. Okinaga, A. Kanda, K. Zayasu, T. Sasaki, M. Asada, et al. Nitroglycerin Treatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6748 - 6757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Brennan, K. Jirstrom, A. Kronblad, R. C. Millikan, G. Landberg, M. J. Duffy, L. Ryden, W. M. Gallagher, and S. L. O'Brien CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. Clin. Cancer Res., November 1, 2006; 12(21): 6421 - 6431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Choi, Y.-S. Chun, S.-W. Kim, M.-S. Kim, and J.-W. Park Curcumin Inhibits Hypoxia-Inducible Factor-1 by Degrading Aryl Hydrocarbon Receptor Nuclear Translocator: A Mechanism of Tumor Growth Inhibition Mol. Pharmacol., November 1, 2006; 70(5): 1664 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tomiyama, S. Serizawa, K. Tachibana, K. Sakurada, H. Samejima, Y. Kuchino, and C. Kitanaka Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors bax and bak. J Natl Cancer Inst, October 18, 2006; 98(20): 1462 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Y Isa, T H Ward, C M L West, N J Slevin, and J J Homer Hypoxia in head and neck cancer Br. J. Radiol., October 1, 2006; 79(946): 791 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Generali, S. B Fox, A. Berruti, M. P Brizzi, L. Campo, S. Bonardi, S. M Wigfield, P. Bruzzi, A. Bersiga, G. Allevi, et al. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 921 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hussein, E. J. Estlin, C. Dive, and G. W.J. Makin Chronic hypoxia promotes hypoxia-inducible factor-1{alpha}-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2241 - 2250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Generali, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, S. Wigfield, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, et al. Hypoxia-Inducible Factor-1{alpha} Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4562 - 4568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Li, X. Lin, A. R. Shoemaker, D. H. Albert, S. W. Fesik, and Y. Shen Hypoxia-Inducible Factor-1 Inhibition in Combination with Temozolomide Treatment Exhibits Robust Antitumor Efficacy In vivo Clin. Cancer Res., August 1, 2006; 12(15): 4747 - 4754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhang, S.-Y. Wang, A. C. Nottke, J. V. Rocheleau, D. W. Piston, and R. H. Goodman Redox sensor CtBP mediates hypoxia-induced tumor cell migration PNAS, June 13, 2006; 103(24): 9029 - 9033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Connolly, S. Braunstein, S. Formenti, and R. J. Schneider Hypoxia Inhibits Protein Synthesis through a 4E-BP1 and Elongation Factor 2 Kinase Pathway Controlled by mTOR and Uncoupled in Breast Cancer Cells Mol. Cell. Biol., May 15, 2006; 26(10): 3955 - 3965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chakraborty, H. Rangaswami, S. Jain, and G. C. Kundu Hypoxia Regulates Cross-talk between Syk and Lck Leading to Breast Cancer Progression and Angiogenesis J. Biol. Chem., April 21, 2006; 281(16): 11322 - 11331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Franco, S. Man, L. Chen, U. Emmenegger, Y. Shaked, A. M. Cheung, A. S. Brown, D. J. Hicklin, F. S. Foster, and R. S. Kerbel Targeted Anti-Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia. Cancer Res., April 1, 2006; 66(7): 3639 - 3648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yasuda, M. Yamaya, K. Nakayama, T. Sasaki, S. Ebihara, A. Kanda, M. Asada, D. Inoue, T. Suzuki, T. Okazaki, et al. Randomized Phase II Trial Comparing Nitroglycerin Plus Vinorelbine and Cisplatin With Vinorelbine and Cisplatin Alone in Previously Untreated Stage IIIB/IV Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2006; 24(4): 688 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kaper, N. Dornhoefer, and A. J. Giaccia Mutations in the PI3K/PTEN/TSC2 Pathway Contribute to Mammalian Target of Rapamycin Activity and Increased Translation under Hypoxic Conditions Cancer Res., February 1, 2006; 66(3): 1561 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Emmenegger, G. C. Morton, G. Francia, Y. Shaked, M. Franco, A. Weinerman, S. Man, and R. S. Kerbel Low-Dose Metronomic Daily Cyclophosphamide and Weekly Tirapazamine: A Well-Tolerated Combination Regimen with Enhanced Efficacy That Exploits Tumor Hypoxia Cancer Res., February 1, 2006; 66(3): 1664 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Manka, Z. Spicer, and D. E. Millhorn Bcl-2/Adenovirus E1B 19 kDa Interacting Protein-3 Knockdown Enables Growth of Breast Cancer Metastases in the Lung, Liver, and Bone Cancer Res., December 15, 2005; 65(24): 11689 - 11693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mayer, M. Hockel, and P. Vaupel Carbonic Anhydrase IX Expression and Tumor Oxygenation Status Do Not Correlate at the Microregional Level in Locally Advanced Cancers of the Uterine Cervix Clin. Cancer Res., October 15, 2005; 11(20): 7220 - 7225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhang, X. Tang, Q. Y. Lu, Z. F. Zhang, J. Brown, and A. D. Le Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1{alpha} and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells Mol. Cancer Ther., October 1, 2005; 4(10): 1465 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Cristini, H. B. Frieboes, R. Gatenby, S. Caserta, M. Ferrari, and J. Sinek Morphologic Instability and Cancer Invasion Clin. Cancer Res., October 1, 2005; 11(19): 6772 - 6779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A S K Dzik-Jurasz Pelvic malignancy: integrating form and function Br. J. Radiol., October 1, 2005; 78(Special_Issue_2): S86 - S93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Suzuki, G.-i. Kusakai, Y. Shimojo, J. Chen, T. Ogura, M. Kobayashi, and H. Esumi Involvement of Transforming Growth Factor-{beta}1 Signaling in Hypoxia-induced Tolerance to Glucose Starvation J. Biol. Chem., September 9, 2005; 280(36): 31557 - 31563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bilton, N. Mazure, E. Trottier, M. Hattab, M.-A. Dery, D. E. Richard, J. Pouyssegur, and M. C. Brahimi-Horn Arrest-defective-1 Protein, an Acetyltransferase, Does Not Alter Stability of Hypoxia-inducible Factor (HIF)-1{alpha} and Is Not Induced by Hypoxia or HIF J. Biol. Chem., September 2, 2005; 280(35): 31132 - 31140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. An and M. B. Rettig Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity Mol. Cell. Biol., September 1, 2005; 25(17): 7546 - 7556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Solomon, D. Binns, P. Roselt, L. I. Weibe, G. A. McArthur, C. Cullinane, and R. J. Hicks Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging Mol. Cancer Ther., September 1, 2005; 4(9): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Raval, K. W. Lau, M. G. B. Tran, H. M. Sowter, S. J. Mandriota, J.-L. Li, C. W. Pugh, P. H. Maxwell, A. L. Harris, and P. J. Ratcliffe Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma Mol. Cell. Biol., July 1, 2005; 25(13): 5675 - 5686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. L. Bard, A. Amelink, V. N. Hegt, W. J. Graveland, H. J. C. M. Sterenborg, H. C. Hoogsteden, and J. G. J. V. Aerts Measurement of Hypoxia-related Parameters in Bronchial Mucosa by Use of Optical Spectroscopy Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1178 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-O. Yoon, S. Shin, and A. M. Mercurio Hypoxia Stimulates Carcinoma Invasion by Stabilizing Microtubules and Promoting the Rab11 Trafficking of the {alpha}6{beta}4 Integrin Cancer Res., April 1, 2005; 65(7): 2761 - 2769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Robbins, S. M. Lee, A. H Filipovich, P. Szigligeti, L. Neumeier, M. Petrovic, and L. Conforti Hypoxia modulates early events in T cell receptor-mediated activation in human T lymphocytes via Kv1.3 channels J. Physiol., April 1, 2005; 564(1): 131 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Taghian, R. Abi-Raad, S. I. Assaad, A. Casty, M. Ancukiewicz, E. Yeh, P. Molokhia, K. Attia, T. Sullivan, I. Kuter, et al. Paclitaxel Decreases the Interstitial Fluid Pressure and Improves Oxygenation in Breast Cancers in Patients Treated With Neoadjuvant Chemotherapy: Clinical Implications J. Clin. Oncol., March 20, 2005; 23(9): 1951 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M M Vleugel, A E Greijer, A Shvarts, P van der Groep, M van Berkel, Y Aarbodem, H van Tinteren, A L Harris, P J van Diest, and E van der Wall Differential prognostic impact of hypoxia induced and diffuse HIF-1{alpha} expression in invasive breast cancer J. Clin. Pathol., February 1, 2005; 58(2): 172 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Samuni, U. Kasid, E. Y. Chuang, S. Suy, W. DeGraff, M. C. Krishna, A. Russo, and J. B. Mitchell Effects of Hypoxia on Radiation-Responsive Stress-Activated Protein Kinase, p53, and Caspase 3 Signals in TK6 Human Lymphoblastoid Cells Cancer Res., January 15, 2005; 65(2): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Arcasoy, K. Amin, S.-C. Chou, Z. A. Haroon, M. Varia, and J. A. Raleigh Erythropoietin and Erythropoietin Receptor Expression in Head and Neck Cancer: Relationship to Tumor Hypoxia Clin. Cancer Res., January 1, 2005; 11(1): 20 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Hoogsteen, H. A.M. Marres, K. I.E.M. Wijffels, P. F.J.W. Rijken, J. P.W. Peters, F. J.A. van den Hoogen, E. Oosterwijk, A. J. van der Kogel, and J. H.A.M. Kaanders Colocalization of Carbonic Anhydrase 9 Expression and Cell Proliferation in Human Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2005; 11(1): 97 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-G. Yoo, M. G. Yeo, D. K. Kim, H. Park, and M.-O. Lee Novel Function of Orphan Nuclear Receptor Nur77 in Stabilizing Hypoxia-inducible Factor-1{alpha} J. Biol. Chem., December 17, 2004; 279(51): 53365 - 53373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Hutchison, H. R. Valentine, J. A. Loncaster, S. E. Davidson, R. D. Hunter, S. A. Roberts, A. L. Harris, I. J. Stratford, P. M. Price, and C. M. L. West Hypoxia-Inducible Factor 1{alpha} Expression as an Intrinsic Marker of Hypoxia: Correlation with Tumor Oxygen, Pimonidazole Measurements, and Outcome in Locally Advanced Carcinoma of the Cervix Clin. Cancer Res., December 15, 2004; 10(24): 8405 - 8412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-T. Hwang, M. Lee, S.-N. Jung, H.-J. Lee, I. Kang, S.-S. Kim, and J. Ha AMP-activated protein kinase activity is required for vanadate-induced hypoxia-inducible factor 1{alpha} expression in DU145 cells Carcinogenesis, December 1, 2004; 25(12): 2497 - 2507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhattacharya, K. Toth, R. Mazurchuk, J. A. Spernyak, H. K. Slocum, L. Pendyala, R. Azrak, S. Cao, F. A. Durrani, and Y. M. Rustum Lack of Microvessels in Well-Differentiated Regions of Human Head and Neck Squamous Cell Carcinoma A253 Associated with Functional Magnetic Resonance Imaging Detectable Hypoxia, Limited Drug Delivery, and Resistance to Irinotecan Therapy Clin. Cancer Res., December 1, 2004; 10(23): 8005 - 8017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Dragowska, C. Warburton, D. T.T. Yapp, A. I. Minchinton, Y. Hu, D. N. Waterhouse, K. Gelmon, K. Skov, J. Woo, D. Masin, et al. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization Mol. Cancer Res., November 1, 2004; 2(11): 606 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vaupel and L. Harrison Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response Oncologist, November 1, 2004; 9(suppl_5): 4 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vaupel The Role of Hypoxia-Induced Factors in Tumor Progression Oncologist, November 1, 2004; 9(suppl_5): 10 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Harrison and K. Blackwell Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy? Oncologist, November 1, 2004; 9(suppl_5): 31 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Blackwell, P. Gascon, G. Sigounas, and L. Jolliffe rHuEPO and Improved Treatment Outcomes: Potential Modes of Action Oncologist, November 1, 2004; 9(suppl_5): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Bennewith and R. E. Durand Quantifying Transient Hypoxia in Human Tumor Xenografts by Flow Cytometry Cancer Res., September 1, 2004; 64(17): 6183 - 6189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Okami, D. M. Simeone, and C. D. Logsdon Silencing of the Hypoxia-Inducible Cell Death Protein BNIP3 in Pancreatic Cancer Cancer Res., August 1, 2004; 64(15): 5338 - 5346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. F. Yang, R. T. Poon, J. To, D. W. Ho, and S. T. Fan The Potential Role of Hypoxia Inducible Factor 1{alpha} in Tumor Progression after Hypoxia and Chemotherapy in Hepatocellular Carcinoma Cancer Res., August 1, 2004; 64(15): 5496 - 5503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kaufman, O. Scharf, J. Arbeit, M. Ashcroft, J. M. Brown, R. K. Bruick, J. D. Chapman, S. M. Evans, A. J. Giaccia, A. L. Harris, et al. Proceedings of the Oxygen Homeostasis/Hypoxia Meeting Cancer Res., May 1, 2004; 64(9): 3350 - 3356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Suzuki, J. Lu, G.-i. Kusakai, A. Kishimoto, T. Ogura, and H. Esumi ARK5 Is a Tumor Invasion-Associated Factor Downstream of Akt Signaling Mol. Cell. Biol., April 15, 2004; 24(8): 3526 - 3535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Dong and J. Wang Hypoxia Selection of Death-resistant Cells: A ROLE FOR Bcl-XL J. Biol. Chem., March 5, 2004; 279(10): 9215 - 9221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mizukami, J. Li, X. Zhang, M. A. Zimmer, O. Iliopoulos, and D. C. Chung Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer Cancer Res., March 1, 2004; 64(5): 1765 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ameri, C. E. Lewis, M. Raida, H. Sowter, T. Hai, and A. L. Harris Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells Blood, March 1, 2004; 103(5): 1876 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rofstad, B. Mathiesen, and K. Galappathi Increased Metastatic Dissemination in Human Melanoma Xenografts after Subcurative Radiation Treatment: Radiation-induced Increase in Fraction of Hypoxic Cells and Hypoxia-induced Up-Regulation of Urokinase-Type Plasminogen Activator Receptor Cancer Res., January 1, 2004; 64(1): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Mahabeleshwar and G. C. Kundu Tyrosine Kinase p56lck Regulates Cell Motility and Nuclear Factor {kappa}B-mediated Secretion of Urokinase Type Plasminogen Activator through Tyrosine Phosphorylation of I{kappa}B{alpha} following Hypoxia/Reoxygenation J. Biol. Chem., December 26, 2003; 278(52): 52598 - 52612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Raghunand, R A Gatenby, and R J Gillies Microenvironmental and cellular consequences of altered blood flow in tumours Br. J. Radiol., December 1, 2003; 76(suppl_1): S11 - S22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vaupel, A. Mayer, S. Briest, and M. Hockel Oxygenation Gain Factor: A Novel Parameter Characterizing the Association between Hemoglobin Level and the Oxygenation Status of Breast Cancers Cancer Res., November 15, 2003; 63(22): 7634 - 7637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Pantuck, G. Zeng, A. S. Belldegrun, and R. A. Figlin Pathobiology, Prognosis, and Targeted Therapy for Renal Cell Carcinoma: Exploiting the Hypoxia-Induced Pathway Clin. Cancer Res., October 15, 2003; 9(13): 4641 - 4652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Aft, J. S. Lewis, F. Zhang, J. Kim, and M. J. Welch Enhancing Targeted Radiotherapy by Copper(II)diacetyl- bis(N4-methylthiosemicarbazone) Using 2-Deoxy-D-Glucose Cancer Res., September 1, 2003; 63(17): 5496 - 5504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Macpherson, S. S.W. Ng, S. L. Forbes, G. Melillo, T. Karpova, J. McNally, T. P. Conrads, T. D. Veenstra, A. Martinez, F. Cuttitta, et al. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay Mol. Cancer Ther., September 1, 2003; 2(9): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Palayoor, P. J. Tofilon, and C. N. Coleman Ibuprofen-mediated Reduction of Hypoxia-inducible Factors HIF-1{alpha} and HIF-2{alpha} in Prostate Cancer Cells Clin. Cancer Res., August 1, 2003; 9(8): 3150 - 3157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Coleman Linking Radiation Oncology and Imaging through Molecular Biology (or Now That Therapy and Diagnosis Have Separated, It's Time to Get Together Again!) Radiology, July 1, 2003; 228(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bachtiary, M. Schindl, R. Potter, B. Dreier, T. H. Knocke, J. A. Hainfellner, R. Horvat, and P. Birner Overexpression of Hypoxia-inducible Factor 1{alpha} Indicates Diminished Response to Radiotherapy and Unfavorable Prognosis in Patients Receiving Radical Radiotherapy for Cervical Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2234 - 2240. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||